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Abstract 
Background: Ardipusilloside‑I (ADS‑I) is a triterpenoid saponin extracted from Chinese medicinal herb Ardisiapusill 
A. DC. Previous studies have demonstrated the potent anti‑tumor activities of ADS‑I both in vitro and in vivo, and its 
main metabolites (M1 and M2) from human intestinal bacteria. However, the physicochemical properties and intes‑
tinal permeation rate of ADS‑I and its metabolites are not understood. In this study, the octanol/water distribution 
coefficients (logP) of ADS‑I and metabolites were investigated using standard shake flask technique, and their perme‑
ability properties was investigated across Caco‑2 cells monolayer.
Results: The logP of ADS‑I, M1 and M2 was −0.01, 0.95 ± 0.04, 1.57 ± 0.11, respectively. The Papp values of ADS‑
I, M1 and M2 (in 10 μmol/L) across Caco‑2 cell monolayers from the apical (AP) to basolateral (BL) direction were 
1.88 ± 0.21 × 10−6 cm·s−1, 4.30 ± 0.43 × 10−6 cm·s−1, 4.74 ± 0.47 × 10−6 cm·s−1, respectively.
Conclusion: Our data indicated that ADS‑I has the poorer intestinal absorption than its metabolites (M1 and M2) in 
these experimental systems, suggesting that the metabolites of ADS‑I may be the predominant products absorbed by 
the intestine when ADS‑I is administered orally.
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Background
Ardipusilloside-I (ADS-I) [1] is a major bioactive triter-
penoid saponin isolated from Chinese medicinal herb 
Ardisiapusill A. DC (Mysinaceae). The anti-tumor activ-
ity of this compound was first reported by Dr. Wang’s 
group [2], followed by many preclinical studies, show-
ing that ADS-I induces tumor cell apoptosis and inhibits 
tumor cell growth, invasion and metastasis both in vitro 
and in  vivo [3–6]. Pharmacokinetic study of ADS-I in 
rats shows that this compound has a poor intestinal 
absorption and the oral bioavailability [7]. Recently, we 
have shown that ADS-I could be mainly metabolized by 
human intestinal bacteria to metabolite M1 and M2 as 
shown in Fig. 1, in which the main metabolic pathway is 
deglycosylation of ADS-I through stepwise cleavage of 
sugar moieties [8]. These findings imply that these metab-
olites of ADS-I may be the primary active substances for 
its inhibitory activity against the growth of the tumor 
in vivo after oral administration, which however remains 
unknown. It has been known that the biological activities 
of drugs depend not only on their chemical structures, 
but also on their degree of lipophilic and membrane per-
meation that facilitate them across the cell membrane [9]. 
Although a previous study has revealed the poor intes-
tinal absorption as well as a low oral bioavailability of 
ADS-I [7], the oral pharmacokinetic properties of ADS-I 
and its metabolites in humans have not investigated of 
yet. Evidence in literature indicates that deglycosylation 
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of ginsenoside by intestinal bacteria to deglycosylated 
metabolites results in enhancing the permeability of the 
intestine, better adsorption into systemic circulation 
and exerting pharmacological effects of the ginsenoside 
[10–12]. Thus, we speculated that the deglycosylation 
of ADS-I to the metabolites (M1 and M2) might medi-
ate the intestinal absorption of ADS-1 for increased oral 
bioavailability.
Lipophilicity, commonly expressed as octanol/water 
distribution coefficient (log P), has been considered as 
one important measurement of drug physicochemi-
cal parameters in drug discovery process to predict the 
pharmacokinetic properties and intestinal absorption of 
a drug [13, 14]. Caco-2 cell monolayer has been widely 
accepted as a standard in  vitro model for prediction of 
drug absorption across human intestine and for mecha-
nistic studies of intestinal drug transport since these cells 
show morphological and functional similarities to human 
small intestinal epithelial cells [15–17]. The objective of 
this study was designed to measure the logP of ADS-I 
and its metabolites using standard shake flask technique, 
and their permeability properties using Caco-2 cells 
monolayer. Thus, we could determine whether the prod-
ucts of ADS-I biotransformation by human intestinal 
bacteria played a role in the membrane permeability of 
ADS-I in human intestine.
Results and discussion
LogP of ADS‑I and its metabolites in octanol/water
The LogP of ADS-I and its metabolites were deter-
mined by using standard shake flask method and HPLC-
ELSD technique. The logarithm of logP values of ADS-I 
and its metabolites were shown in Table  1, indicating 
that the logP values of ADS-I, M1 and M2 were −0.01, 
0.95  ±  0.04, 1.57  ±  0.11 respectively. According to a 
previous study [18], the value of logP from one to three 
suggests that the drug is easily absorbed by the intestine, 
and below zero poorly absorbed. Thus, our experiment 
results indicated that ADS-I was difficult or less to be 
absorbed, whereas M2 had the highest absorption. Fur-
thermore, the data also showed that there was a correla-
tion between molecular weight and lipophilicity of ADS-I 
and its metabolites. As a matter of fact, the absorption 
extent of these three compounds was negatively corre-
lated with their molecular polarity and molecular weight. 
Indeed, the larger the molecular polarity and molecular 
weight of a compound, the more difficultly it is absorbed 
[19, 20]. ADS-I has the highest polarity and molecular 
weight compared to M1 and M2, the lower logP value of 
ADS-I suggests that this compound has a poor absorp-
tion in human intestine after oral administration. These 
results were in agreement with the low oral bioavailabil-
ity of ADS-I in rats as reported previously [7], and may 
suggest that these metabolites may have better absorp-
tion than ADS-I.
The permeation characteristics of ADS‑I and its 
metabolites across Caco‑2 cell monolayer
Cytotoxicity assay
The viability of cells was measured using MTT assay to 
evaluate the cytotoxicity of ADS-I and its metabolites 





















































Fig. 1 Chemical structures of ADS‑I and its metabolites (M1, M2)
Table 1 The octanol/water partition coefficients (logP) 
of ADS-I and its metabolites in phosphate-buffers (pH = 7.4)
Date are presented as mean ± SD (n = 3)
ADS‑I and its metabolites MW (g/mol) Log P (Mean ± SD)
ADS‑I 1074 −0.01
M1 912 0.95 ± 0.04
M2 766 1.57 ± 0.11
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Generally, cell viability of more than 90 % indicated that 
the compounds at the stated concentrations were non-
toxic to the cells [21]. As shown in Fig. 2, ADS-I, M1 and 
M2 at 0–10  µmol/L were nontoxic to the Caco-2 cells 
after incubation for 4  h. Therefore, 2, 5 and 10  µmol/L 
of each compound was used for two-way transport 
experiments.
Characters of Caco‑2 cell monolayer
In order to confirm if the cells in culture formed a mon-
olayer, the TEER values of the Caco-2 cell monolayer were 
measured at 5, 7, 9, 13, 17, 21 days after seeding, respec-
tively. As shown in Fig. 3, the Caco-2 cell monolayer was 
completely formed on day 21 with TEER values above 
400 Ω cm2 and was used for the transport experiments. 
In addition, electron microscope revealed the intact tight 
junctions in the Caco-2 cell monolayer (Fig. 4). Thus, the 
Caco-2 cell monolayer model established herein was vali-
dated for the permeation experiment.
Two‑way transport of ADS‑I and its metabolites 
across Caco‑2 cell monolayer
The permeability change of ADS-I, M1, or M2 across 
the Caco-2 cell monolayer at different concentrations 
from AP to BL direction was shown in Fig.  5, and the 
accumulated transfer amounts of ADS-I, M1 or M2 
increased with a prolonged time of incubation as illus-
trated in Fig. 5a–c. With the same concentration, the flux 
amounts of M1 and M2 in AP to BL direction were simi-
lar, and both were greater than that of ADS-I (Fig.  5d). 
As shown in Fig. 6, the Papp value of ADS-I (10 µmol/L) 
was 1.88 ±  0.21 ×  10−6  cm·s−1 for AP to BL direction, 
and was 0.69 ± 0.15 × 10−6 cm·s−1 for BL to AP direc-
tion in 120  min, which was considered to have a poor 
permeability and absorption rate similar to in  vivo [7]. 
However, with stepwise removal of glycosyl groups in 
the metabolites (M1 and M2), the Papp values of these 
compounds increased and were higher than those of 
ADS-I across the Caco-2 cell monolayer in both direc-
tions. The Papp values of M1 (10 µmol/L) in the direction 
of AP - BL and BL - AP were 4.30 ± 0.43 × 10−6 cm·s−1 
and 1.76  ±  0.26  ×  10−6  cm·s−1 respectively, and of 
M2 (10  µmol/L) were 4.74  ±  0.47  ×  10−6  cm·s−1 and 
2.12 ± 0.23 × 10−6 cm·s−1 respectively. These data sug-
gested that metabolites M1 and M2 were easier to be 
absorbed than ADS-I by the intestine. 
The Papp values of ADS-I, M1 or M2 at different con-
centrations across the Caco-2 cell monolayer in both 
directions were shown in Table  2, indicating that the 
Papp values of these compounds gradually decreased with 
the increase of their concentration respectively. Accord-
ing to the formula (“The two-way transport experiment” 
section), the transport amounts of ΔQ increased along 
with Δt at the same concentration (C0), but the increased 
speed of ΔQ became slower along with the Δt, which 
meant that the value of ΔQ/Δt relatively decreased, 
thus the apparent permeability coefficient (Papp) was 
also reduced. We inferred that the transport of ADS-I, 
M1 and M2 across the Caco-2 cell monolayer partially 
depend on their concentration, and some carrier might 
participate in the process of transportation. Besides,the 
Papp values of ADS-I and its metabolites (M1 and M2) 
in AP to BL direction were greater than that in BL to 
AP direction across the Caco-2 cell monolayer, and 
efflux ratio (ER) were all 0.3–0.6. These data suggested 
that ADS-I and its metabolites (M1 and M2) could be 
absorbed across intestinal epithelial cells in a passive 
absorption pattern, and the transport processes of these 
Fig. 2 Cytotoxicity of ADS‑I, M1 and M2 on Caco‑2 cell monolayers 
using the MTT assay. Data are expressed as mean ± SD (n = 3)
Fig. 3 TEER values of Caco‑2 cell monolayers at different time points. 
Data are represented as mean ± SD (n = 3)
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Fig. 4 Caco‑2 cell morphology, a the 2nd day; b the 7th day; c the 21st day
Fig. 5 Change of accumulated amount of a different concentrations of ADS‑I, b different concentration of M1, c different concentration of M2, d 
ADS‑I, M1, M2 (10 µmol/L) across Caco‑2 cell monolayer from AP to BL direction. Date represent the mean ± SD from three replicates
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compounds might not be the substrate of apical efflux 
transporters.
It has been known that compounds with Papp val-
ues less than 2.0 ×  10−6  cm·s−1 are considered to have 
a low absorption (0–20 %), while those with Papp values 
between 2.0  ×  10−6  cm·s−1 and 10  ×  10−6  cm·s−1 are 
considered to have a moderate absorption (20−70 %), and 
those with Papp values of higher than 10 ×  10−6  cm·s−1 
are considered to have a high absorption (70–100 %) [22]. 
In this study, the transport of the major metabolites (M1, 
M2) of ADS-I was compared with the parent compound 
ADS-I in the same system, and showed that ADS-I is a 
poorly absorbed compound, M1 and M2 belong to the 
moderately absorbed compound.
Structure‑intestinal permeability relationship
Physicochemical characters, such as log P, log D and 
polar surface area, are generally measured for the predic-
tion of drug permeability. To study the structure-intesti-
nal permeability relationship, Papp values of ADS-I and its 
metabolites (M1 and M2) across Caco-2 cell monolayer 
were compared with their logP and molecular weight. In 
Fig. 7a, the Papp values of ADS-I and its metabolites (M1 
and M2) transported from apical to basolateral direction 
(C0 10  μM) were plotted as a function of their molecu-
lar weight, with stepwise removal of glycosyl groups in 
the metabolites (M1 and M2), the Papp values of these 
compounds increased and were higher than the parent 
compound ADS-I. Figure  7b showed the relationship 
between Papp and logP of ADS-I and its metabolites (M1 
and M2), the Papp (AP to BL direction) values increased 
with an increase of LogP. These findings indicated that 
ADS-I and its metabolites (M1 and M2) across Caco-2 
cell monolayer were well correlated with their logP and 
Fig. 6 The Papp values of ADS‑I, M1 and M2 (10 μmol/L) across Caco‑2 
cell monolayer from AP to BL direction and vice versa in 120 min. 
Date are presented as mean ± SD (n = 3). **P < 0.01 compared to the 
control group (ADS‑I)
Table 2 The Papp values of  ADS-I, M1 and  M2 at  different 
concentrations across  the Caco-2 cell monolayer in  both 
directions in 120 min
Date are presented as mean ± SD (n = 3).  






ADS‑I 2 6.66 ± 1.32 2.50 ± 0.53 0.38
5 3.10 ± 0.33 1.66 ± 0.24 0.54
10 1.88 ± 0.21 0.69 ± 0.15 0.37
M1 2 9.13** ± 1.65 3.14** ± 0.58 0.34
5 6.07** ± 0.74 3.45** ± 0.67 0.57
10 4.30** ± 0.43 1.76** ± 0.26 0.41
M2 2 10.48** ± 1.21 4.53** ± 0.57 0.43
5 6.76** ± 0.85 2.60** ± 0.43 0.38
10 4.74** ± 0.47 2.12** ± 0.23 0.45
Fig. 7 The apparent permeability (Papp) vs. molecular weight (a), and 
logP (b) of ADS‑I, M1 and M2 from the apical to basolateral direction 
across Caco‑2 cell monolayer. Values are represents mean ± SD 
(n = 3)
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molecular weight, and metabolites M1 and M2 exhibited 
higher permeability absorption than ADS-I.
Conclusion
In this study, the octanol/water distribution coefficients 
(logP) and membrane permeability properties of ADS-I 
and its metabolites (M1, M2) were investigated to pre-
dict their intestinal absorption in human. Our data sug-
gest that ADS-I has a poor intestinal absorption in 
human after oral administration. Metabolites (M1, M2) 
of ADS-I, biotransformed by human intestinal bacteria, 
exhibited a moderate absorption as well as higher per-
meability than ADS-I in the following decreasing order: 
M2 > M1 > ADS-I. These results may suggest that these 
metabolites may have better absorption than ADS-I, and 
thus could be the major substances in vivo for inhibitory 
activities against the growth of tumor after oral adminis-
tration of ADS-I. In summary, the present results provide 
useful information to predict the oral bioavailability of 




ADS-I and its metabolites M1, M2 (purity  >  95  %) 
were provided by Dr. X.-J. Wang at the Department 
of Pharmacy, School of Stomatology, the Fourth Mili-
tary Medical University (Xi’an, China). Ginsenoside 
Re (purity  >  93.7  %) was purchased from the National 
Institute for Food and Drug Control (Beijing, China), 
6-well-Transwell plates (insert diameter 24 mm, pore size 
0.4  μm, membrane growth area 4.67  cm2) and 96-well 
plates from Corning Costar (Cambridge, MA, USA), 
Millicell-ERS system from Millipore Corporation (Bed-
ford, OH, USA), Dulbecco’s Modified Eagle’s medium 
(DMEM) and fetal bovine serum (FBS) from HyClone 
Laboratories (Logan, UT, USA), HPLC grade acetoni-
trile and methanol from Fisher Scientific (Pittsburgh, PA, 
USA), and Penicillin–streptomycin and 0.25  % trypsin–
EDTA solutions from Solarbio (Beijing, China). Other 
reagents were of analytical purity.
Determination of Log P of ADS‑I metabolites by HPLC–
ELSD
HPLC–ELSD instrumentation and chromatographic 
conditions
ADS-I and its metabolites (M1, M2) concentrations in 
two phases were quantified using a LC-20A high perfor-
mance liquid chromatograph (Shimadzu Corporation, 
Kyoto, Japan) equipped with a Alltech type 3300 evapo-
rative light-scattering detector (Alltech Associates, Deer-
field, USA). A Diamonsil C18 (2) column (4.6 × 250 mm, 
5  µm) from Diamonsil Technologies (Beijing, China) 
was used for all the compound separations, and the col-
umn temperature was maintained at 25  °C. The mobile 
phase consisted of 25  % (A) ultra-pure water and 75  % 
(B) methanol using an isocratic elution. The flow rate was 
1 mL/min, and the injection volume was 10 µl. The ELSD 
was set to a probe temperature at 60 °C, a gain of 1 and 
the nebulizer gas nitrogen at a flow of 2.0 L/min.
The liner regression equation for ADS-I was 
y  =  1.9726 x  +  4.6654 (r  =  0.9995), with a good lin-
earity over the range from 0.1002 to 0.9018  mg/mL, 
y = 1.8255x + 4.8093 (r = 0.9993) for M1 with a good 
linearity over the range from 0.1018 to 0.9162  mg/mL, 
and y = 1.8006x + 4.8211 (r = 0.9992) for M2 with a 
good linearity over the range from 0.1010 to 0.9090 mg/
mL.
LogP of ADS‑I and its metabolites with a shake flask method 
[23, 24]
Prior to the distribution experiment, octanol and phos-
phate buffer (10 mM, PH 7.4) were mutually saturated at 
room temperature. ADS-I and its metabolites (M1, M2) 
were dissolved in DMSO at final concentration of 20 mg/
mL, and a volume of 50 µL compound in DMSO solu-
tion was added to the octanol/phosphate buffer (1:1, v/v) 
system. After vortex mixing, the mixtures were orbital 
shaken for 48  h at 37  °C, and consequently the phases 
were separated. The solution with two phases were then 
centrifuged at 13,000 rpm min−1 for 10 min. The concen-
tration of ADS-I and metabolites (M1, M2) in both the 
phosphate buffer and n-octanol after the shaking was 
determined by using HPLC-ELSD as described above.
Data analysis
The experiments measured logP was calculated using the 
following equation: log P = log Co
/
Cw where Co was the 
concentration of a compound in the n-octanol phase, Cw 
is the concentration of the compound in the phosphate 
buffer phase.
The permeation characteristics of ADS‑I and its 
metabolites across Caco‑2 cell monolayer
Cell culture
The human colon Caco-2 cells were purchased from the 
Cell Bank of the Chinese Academy of Sciences (Shang-
hai, China), and were cultured in DMEM with 10 % FBS 
(inactivation at 56  °C for 30  min), 1  % NEAA and 1  % 
antibiotics (100 IU/ml penicillin and 100 µg/ml strepto-
mycin in a humidified atmosphere of 5 % CO2 at 37 °C.
Cytotoxicity assay
The cytotoxicity of ADS-I and its metabolites (M1, M2) 
against Caco-2 cells was evaluated by MTT assay. In 
brief, 100 µL of Caco-2 cell suspension (2 × 104 cells/mL) 
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per well was seeded in 96-well plates, followed by 24  h 
incubation (37  °C, 5 % CO2). ADS-I and its metabolites 
(M1, M2) were dissolved in DMSO (<1  ‰) and diluted 
in DMEM, A volume of 100 µL compounds solution 
were added to each well and made the final concentra-
tions were 5, 10, 20, 50, 100 µM, respectively. After 4 h 
incubation, 20 μL of 5 mg/mL MTT was added to each 
well and incubated for another 4 h. Then the medium was 
removed and cells were dissolved in 150 µl DMSO with 
gentle shaking for 10 min, and the optical density (OD) 
was measured with an ELX800 reader (Bio-Tek instru-
ments, Inc., Winooski, VT, USA) at 490  nm. Untreated 
cells were used as controls. The doses of a compound 
with survival rate higher than 90  % were considered 
non-cytotoxicity.
The two‑way transport experiment
For transport experiments,Caco-2 cells were seeded 
on the rat tail collagen-coated 6-wells Transwell plates 
(insert diameter 24  mm, pore size 0.4  μm, membrane 
growth area 4.67  cm2) at a density of 1 ×  105 cells/cm2 
and incubated for 19–21 days. The medium was changed 
every 2  days. The integrity and transportation ability of 
the Caco-2 cell monolayer was examined by measur-
ing the transepithelial electrical resistance (TEER) of 
filter-grown cell monolayer with millicell-ERS equip-
ment. Only a monolayer with a TEER value of more than 
400  Ω  cm2 was used for the trans epithelial transport 
experiments.
The transport of ADS-I and its metabolites across 
Caco-2 monolayer was investigated as previously 
described [25, 26]. Before the transport experiment, 
cells were washed three times with warm HBSS (pH 7.4, 
37 °C). Cell monolayer was then incubated for 30 min at 
37 °C in the transport buffer. To measure the apical (AP)-
to-basolated (BL) permeability, 0.5  mL of the transport 
buffer containing different concentrations (2, 5, 10  µM) 
of ADS-I, M1, or M2 was added to AP side of the tran-
swell insert, and 1.5 mL of the HBSS was added to the BL 
chamber. The plates were incubated in an orbital shaker 
at 37 °C, 50 rpm/min. To assess the drugs transport from 
AP to BL, after incubation for 30, 60, 90 or 120  min, a 
volume of 200 μL aliquot was collected from BL side, fol-
lowed by immediately being replenished with an equal 
volume of blank HBSS. For the measurement of BL to AP 
transport, 1.5 mL of the transport buffer containing dif-
ferent concentrations (2, 5, 10 µM) of ADS-I, M1, or M2 
was added to the BL side, and 0.5 mL of the HBSS to AP 
side. A volume of 200 μL aliquot was harvested from AP 
side at time intervals of 30, 60, 90 and 120  min respec-
tively, and immediately replaced with the same volume of 
blank HBSS. The samples were frozen immediately and 
stored at −80 °C before analysis by UHPLC–MS.
In the Caco-2 cell model, the rate of transport was cal-
culated based on the amount transported vs. time curve 
using linear regression. The apparent permeability (Papp) 
presented as an expression of the absorption rate con-
stant was calculated using the following equation,
where Papp was the apparent permeability coefficient 
(cm/s), ΔQ/Δt (µmol/s) represented the appearance rate 
of the test compound on the receiver side, A (4.67 cm2) is 
the surface area of the filter membrane and C0 (µmol/L) 
was the initial concentration in the donor chamber. 
The efflux ratio (Re) was determined by calculating the 
ratio of Papp (B−A) versus Papp (A−B) as the following 
equation,
Sample preparation for UHPLC–ESI–MS/MS assay
A sample (200  μL) from either cellular absorption or 
transport experiments was mixed with 20  μL metha-
nol containing the internal standard (ginsenoside Re, 
0.498  μg/ml). The mixture was vortexed for 60  s. Then 
after centrifugation at 10,000×g for 10  min, 5  μL of 
supernatant was then injected into the LC/MS system. 
Also, 200  μL of standard solutions containing different 
concentrations of ADS-I, M1 or M2 was processed in the 
same way as above. The calibration curves for ADS-I, M1 
or M2 were generated by plotting the peak area ratios of 
the analytes to the internal standard versus the concen-
trations by least-square linear regression.
UHPLC–MS analysis
UHPLC-MS analysis was performed using an Agilent 
1290 Infinity ultra-high performance liquid chroma-
tography (UHPLC) and 6460 type triple quadrupole 
(QQQ) mass spectrometer equipped with electrospray 
ion source (ESI) and Mass Hunter working software ver-
sion B.04.10 (Agilent Technologies, California, USA). A 
Poroshell 120  EC C18 column (2.1  ×  100  mm, 2.7  µm) 
from Agilent Technologies was used as an analytical 
column and the column temperature was maintained 
at 25  °C. The isocratic mobile phase consisted of 40  % 
acetonitrile and 60 % H2O at a flow rate of 0.4 mL/min. 
Quantification was determined using multiple reactions 
monitoring model, and the operating parameters were 
optimized as follows: drying gas (N2) flow rate, 10.0  L/
min; drying gas temperature, 350  °C; nebulizer, 45  psi; 
capillary, 3500  V; fragmentor voltage, 150  V; sheath gas 
temperature, 350 °C; sheath gas flow rate, 11 L/min. The 
precursor-product ion pairs used in MRM mode were: 
m/z 1073.5 →  927.3 for ADS-I, m/z 911.3 →  765.4 for 
M1, m/z 765.4 → 603.1 for M2, 945.5 → 475.3 for Ginse-
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The sensitivity of UHPLC-MS/MS analysis was 
first evaluated for drug quantification. The regres-
sion equation for the standard curve were as follow: 
y = 1.7226x + 0.1239 (r = 0.9995) for ADS-I with the 
range of 0.061–0.980 μg/mL and the lower limit of quanti-
fication was 10 ng/mL; y = 1.4379x + 0.0417 (r = 0.9993) 
for M1 with the range of 0.064–1.020  μg/mL and 
the lower limit of quantification was 8  ng/mL; 
y = 1.2802x + 0.0579 (r = 0.9987) for M2 with the range 
of 0.063–1.000  μg/mL and the lower limit of quantifica-
tion was 6 ng/mL.
Statistical analysis
Data were expressed as means  ±  standard derivation 
(SD). Statistical analysis was performed using the statis-
tical software SPSS16.0 (SPSS Inc., Chicago, IL, USA). 
Student’s t test was used to analyze statistical differences 
between groups. P  <  0.05 was considered statistically 
significant.
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